Jos van der Hage

9PUBLICATIONS
42CO-AUTHORS
Predictive and prognostic markersOncology and carcinogenesis not elsewhere classifiedEthical use of new technologyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

Lotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen

|Aug 10, 2024
Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.

Daan Jan Willem Rauwerdink, Olivier van Not, Melissa de Meza

|Dec 23, 2022
Where Robotic Surgery Meets the Metaverse.

Fijs W B van Leeuwen, Jos A van der Hage

|Nov 26, 2022
Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry.

Daan Jan Willem Rauwerdink, Remco van Doorn, Jos van der Hage

|Nov 11, 2022
Early Prediction and Monitoring of Treatment Response in Gastrointestinal Stromal Tumors by Means of Imaging: A Systematic Review.

Ylva A Weeda, Gijsbert M Kalisvaart, Floris H P van Velden

|Jun 06, 2022
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.

Irene L M Reijers, Alexander M Menzies, Alexander C J van Akkooi

Pageof 2

Frequent Collaborators

4 joint publications

Dirk J Grünhagen

4 joint publications

Michel W Wouters

3 joint publications

Ellen Kapiteijn

3 joint publications

Karijn Suijkerbuijk